This HTML5 document contains 197 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n19http://linked.opendata.cz/resource/drugbank/drug/DB00567/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00567/identifier/national-drug-code-directory/
n32http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/drugbank/dosage/
n30http://www.drugs.com/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00567/identifier/chemspider/
n13http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB00567/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n12http://www.rxlist.com/cgi/generic/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00567/identifier/wikipedia/
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00567/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n28http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00567/identifier/kegg-compound/
n31http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00567/identifier/bindingdb/
n5http://linked.opendata.cz/resource/drugbank/property/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00567/identifier/pubchem-compound/
n9http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00567/identifier/pubchem-substance/
n20http://linked.opendata.cz/ontology/sukl/drug/
n27http://linked.opendata.cz/resource/atc/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00567/identifier/kegg-drug/

Statements

Subject Item
n2:DB00567
rdf:type
n3:Drug
n3:description
A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of cephaloridine or cephalothin, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms. [PubChem]
n3:dosage
n26:271B49F2-363D-11E5-9242-09173F13E4C5 n26:271B49F3-363D-11E5-9242-09173F13E4C5 n26:271B49F4-363D-11E5-9242-09173F13E4C5 n26:271B49F5-363D-11E5-9242-09173F13E4C5 n26:271B49FA-363D-11E5-9242-09173F13E4C5 n26:271B49FB-363D-11E5-9242-09173F13E4C5 n26:271B49FC-363D-11E5-9242-09173F13E4C5 n26:271B49FD-363D-11E5-9242-09173F13E4C5 n26:271B49F6-363D-11E5-9242-09173F13E4C5 n26:271B49F7-363D-11E5-9242-09173F13E4C5 n26:271B49F8-363D-11E5-9242-09173F13E4C5 n26:271B49F9-363D-11E5-9242-09173F13E4C5 n26:271B49FE-363D-11E5-9242-09173F13E4C5 n26:271B49FF-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
1 hour
n3:indication
For the treatment of respiratory tract infections caused by <i>Streptococcus pneumoniae</i> and <i>Streptococcus pyogenes</i>; otitis media due to <i>Streptococcus pneumoniae</i>, <i>Haemophilus influenzae</i>, <i>Staphylococcus aureus</i>, <i>Streptococcus pyogenes</i>, and <i>Moraxella catarrhalis</i>; skin and skin structure infections caused by <i>Staphylococcus aureus</i> and/or <i>Streptococcus pyogenes</i>; bone infections caused by <i>Staphylococcus aureus</i> and/or <i>Proteus mirabilis</i>; genitourinary tract infections, including acute prostatitis, caused by <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, and <i>Klebsiella pneumoniae</i>.
n3:manufacturer
n4:271B49D7-363D-11E5-9242-09173F13E4C5 n4:271B49D8-363D-11E5-9242-09173F13E4C5 n4:271B49D5-363D-11E5-9242-09173F13E4C5 n4:271B49D6-363D-11E5-9242-09173F13E4C5 n4:271B49D9-363D-11E5-9242-09173F13E4C5 n4:271B49DA-363D-11E5-9242-09173F13E4C5 n4:271B49C7-363D-11E5-9242-09173F13E4C5 n4:271B49C8-363D-11E5-9242-09173F13E4C5 n4:271B49CB-363D-11E5-9242-09173F13E4C5 n4:271B49CC-363D-11E5-9242-09173F13E4C5 n4:271B49C9-363D-11E5-9242-09173F13E4C5 n4:271B49CA-363D-11E5-9242-09173F13E4C5 n4:271B49CF-363D-11E5-9242-09173F13E4C5 n4:271B49D0-363D-11E5-9242-09173F13E4C5 n4:271B49CD-363D-11E5-9242-09173F13E4C5 n4:271B49CE-363D-11E5-9242-09173F13E4C5 n4:271B49D3-363D-11E5-9242-09173F13E4C5 n4:271B49D4-363D-11E5-9242-09173F13E4C5 n4:271B49D1-363D-11E5-9242-09173F13E4C5 n4:271B49D2-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00567 n13:DB00567
dcterms:title
Cephalexin
adms:identifier
n11:Cephalexin n14:3534 n15:25541 n16:50139896 n17:C06895 n18:D00263 n19:DB00567 n22:27447 n23:46506749 n24:16714-641-01 n25:PA448883
n3:mechanismOfAction
Cephalexin, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cephalexin interferes with an autolysin inhibitor.
n3:packager
n4:271B49BA-363D-11E5-9242-09173F13E4C5 n4:271B49BB-363D-11E5-9242-09173F13E4C5 n4:271B49B8-363D-11E5-9242-09173F13E4C5 n4:271B49B9-363D-11E5-9242-09173F13E4C5 n4:271B499A-363D-11E5-9242-09173F13E4C5 n4:271B499B-363D-11E5-9242-09173F13E4C5 n4:271B4998-363D-11E5-9242-09173F13E4C5 n4:271B4999-363D-11E5-9242-09173F13E4C5 n4:271B4996-363D-11E5-9242-09173F13E4C5 n4:271B4997-363D-11E5-9242-09173F13E4C5 n4:271B4994-363D-11E5-9242-09173F13E4C5 n4:271B4995-363D-11E5-9242-09173F13E4C5 n4:271B4992-363D-11E5-9242-09173F13E4C5 n4:271B4993-363D-11E5-9242-09173F13E4C5 n4:271B4990-363D-11E5-9242-09173F13E4C5 n4:271B4991-363D-11E5-9242-09173F13E4C5 n4:271B498E-363D-11E5-9242-09173F13E4C5 n4:271B498F-363D-11E5-9242-09173F13E4C5 n4:271B498D-363D-11E5-9242-09173F13E4C5 n4:271B49AA-363D-11E5-9242-09173F13E4C5 n4:271B49AB-363D-11E5-9242-09173F13E4C5 n4:271B49A8-363D-11E5-9242-09173F13E4C5 n4:271B49A9-363D-11E5-9242-09173F13E4C5 n4:271B49A6-363D-11E5-9242-09173F13E4C5 n4:271B49A7-363D-11E5-9242-09173F13E4C5 n4:271B49A4-363D-11E5-9242-09173F13E4C5 n4:271B49A5-363D-11E5-9242-09173F13E4C5 n4:271B49A2-363D-11E5-9242-09173F13E4C5 n4:271B49A3-363D-11E5-9242-09173F13E4C5 n4:271B49A0-363D-11E5-9242-09173F13E4C5 n4:271B49A1-363D-11E5-9242-09173F13E4C5 n4:271B499E-363D-11E5-9242-09173F13E4C5 n4:271B499C-363D-11E5-9242-09173F13E4C5 n4:271B499F-363D-11E5-9242-09173F13E4C5 n4:271B49C6-363D-11E5-9242-09173F13E4C5 n4:271B498C-363D-11E5-9242-09173F13E4C5 n4:271B499D-363D-11E5-9242-09173F13E4C5 n4:271B49B0-363D-11E5-9242-09173F13E4C5 n4:271B49AE-363D-11E5-9242-09173F13E4C5 n4:271B49AF-363D-11E5-9242-09173F13E4C5 n4:271B49AC-363D-11E5-9242-09173F13E4C5 n4:271B49AD-363D-11E5-9242-09173F13E4C5 n4:271B49B6-363D-11E5-9242-09173F13E4C5 n4:271B49B7-363D-11E5-9242-09173F13E4C5 n4:271B49B4-363D-11E5-9242-09173F13E4C5 n4:271B49B5-363D-11E5-9242-09173F13E4C5 n4:271B49B2-363D-11E5-9242-09173F13E4C5 n4:271B49B3-363D-11E5-9242-09173F13E4C5 n4:271B498B-363D-11E5-9242-09173F13E4C5 n4:271B49B1-363D-11E5-9242-09173F13E4C5 n4:271B49C4-363D-11E5-9242-09173F13E4C5 n4:271B49C5-363D-11E5-9242-09173F13E4C5 n4:271B49C2-363D-11E5-9242-09173F13E4C5 n4:271B49C3-363D-11E5-9242-09173F13E4C5 n4:271B49C0-363D-11E5-9242-09173F13E4C5 n4:271B49C1-363D-11E5-9242-09173F13E4C5 n4:271B49BE-363D-11E5-9242-09173F13E4C5 n4:271B49BF-363D-11E5-9242-09173F13E4C5 n4:271B49BC-363D-11E5-9242-09173F13E4C5 n4:271B49BD-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Cephalexin is excreted in the urine by glomerular filtration and tubular secretion. Studies showed that over 90% of the drug was excreted unchanged in the urine within 8 hours.
n3:synonym
Cefalexinum CĂ©falexine Cepexin 7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanic acid CĂ©phalexine Cefalexin Cephacillin Cefalexina Celexin Cepastar 7-beta-(D-alpha-Amino-alpha-phenylacetylamino)-3-methyl-3-cephem-4-carboxylic acid Ceporexin (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid CEX
n3:toxicity
Symptoms of overdose include blood in the urine, diarrhea, nausea, upper abdominal pain, and vomiting. The oral median lethal dose of cephalexin in rats is >5000 mg/kg.
n20:hasAHFSCode
n21:08-12-06-04
n3:foodInteraction
Take on empty stomach: 1 hour before or 2 hours after meals.
n3:proteinBinding
14%
n3:salt
n3:synthesisReference
Peter Faarup, "Method of preparing a sparingly soluble complex of cephalexin." U.S. Patent US4003896, issued May, 1975.
n31:hasConcept
n32:M0003820
foaf:page
n9:kef1213.shtml n12:cephalex.htm n30:cephalexin.html
n3:IUPAC-Name
n5:271B4A04-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4A0A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4A09-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4A06-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4A07-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4A08-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B4A02-363D-11E5-9242-09173F13E4C5 n5:271B4A1A-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B4A1C-363D-11E5-9242-09173F13E4C5 n5:271B4A03-363D-11E5-9242-09173F13E4C5 n5:271B4A00-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B4A01-363D-11E5-9242-09173F13E4C5
n3:pKa
n5:271B4A1D-363D-11E5-9242-09173F13E4C5
n20:hasATCCode
n27:J01DB01
n3:H-Bond-Acceptor-Count
n5:271B4A10-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B4A11-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4A0B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B4A0C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B4A0E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B4A0D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4A0F-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed from the gastrointestinal tract
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
15686-71-2
n3:category
n3:containedIn
n28:271B49DC-363D-11E5-9242-09173F13E4C5 n28:271B49DD-363D-11E5-9242-09173F13E4C5 n28:271B49DB-363D-11E5-9242-09173F13E4C5 n28:271B49EC-363D-11E5-9242-09173F13E4C5 n28:271B49ED-363D-11E5-9242-09173F13E4C5 n28:271B49EA-363D-11E5-9242-09173F13E4C5 n28:271B49EB-363D-11E5-9242-09173F13E4C5 n28:271B49E8-363D-11E5-9242-09173F13E4C5 n28:271B49E9-363D-11E5-9242-09173F13E4C5 n28:271B49E6-363D-11E5-9242-09173F13E4C5 n28:271B49E7-363D-11E5-9242-09173F13E4C5 n28:271B49E4-363D-11E5-9242-09173F13E4C5 n28:271B49E5-363D-11E5-9242-09173F13E4C5 n28:271B49E2-363D-11E5-9242-09173F13E4C5 n28:271B49E3-363D-11E5-9242-09173F13E4C5 n28:271B49E0-363D-11E5-9242-09173F13E4C5 n28:271B49E1-363D-11E5-9242-09173F13E4C5 n28:271B49DE-363D-11E5-9242-09173F13E4C5 n28:271B49DF-363D-11E5-9242-09173F13E4C5 n28:271B49F0-363D-11E5-9242-09173F13E4C5 n28:271B49F1-363D-11E5-9242-09173F13E4C5 n28:271B49EE-363D-11E5-9242-09173F13E4C5 n28:271B49EF-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4A16-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4A18-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4A19-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B4A1B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4A15-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4A14-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4A17-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B4A05-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B4A12-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4A13-363D-11E5-9242-09173F13E4C5